scholarly journals Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases

Cancer ◽  
2012 ◽  
Vol 118 (20) ◽  
pp. 4929-4935 ◽  
Author(s):  
Laurien D. C. Hoefnagel ◽  
Cathy B. Moelans ◽  
S. L. Meijer ◽  
Henk-Jan van Slooten ◽  
Pieter Wesseling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Prognostic Value ◽  
Estrogen Receptor Α ◽  
Breast Cancer Metastases ◽  
Cancer Metastases ◽  
Receptor Conversion

Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological study

2020 ◽  
Vol 148 (3) ◽  
pp. 692-701
Author(s):  
Zong‐Bi Yi ◽  
Pei Yu ◽  
Su Zhang ◽  
Wen‐Na Wang ◽  
Yi‐Qun Han ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidemiological Study ◽  
Breast Cancer Metastases ◽  
Cancer Metastases ◽  
Receptor Conversion

Progesterone receptor status of breast cancer metastases

2001 ◽  
Vol 128 (1) ◽  
pp. 55-60 ◽  
Author(s):  
M. Branković-Magić ◽  
R. Janković ◽  
Z. Nešković-Konstantinović ◽  
D. Nikolić-Vukosavljević
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Progesterone Receptor Status ◽  
Receptor Status ◽  
Breast Cancer Metastases ◽  
Cancer Metastases

scholarly journals Lost but Not Least—Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4755
Author(s):  
Michał Kunc ◽  
Marta Popęda ◽  
Wojciech Biernat ◽  
Elżbieta Senkus
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Neoadjuvant Treatment ◽  
Predictive Biomarkers ◽  
Immunohistochemical Analysis ◽  
Estrogen Receptor Α ◽  
Local Relapse ◽  
Copy Number Loss ◽  
Double Positive

Estrogen receptor α (ERα) and progesterone receptor (PgR) are crucial prognostic and predictive biomarkers that are usually co-expressed in breast cancer (BC). However, 12–24% of BCs present ERα(+)/PgR(−) phenotype at immunohistochemical evaluation. In fact, BC may either show primary PgR(−) status (in chemonaïve tumor sample), lose PgR expression during neoadjuvant treatment, or acquire PgR(−) phenotype in local relapse or metastasis. The loss of PgR expression in ERα(+) breast cancer may signify resistance to endocrine therapy and poorer outcomes. On the other hand, ERα(+)/PgR(−) BCs may have a better response to neoadjuvant chemotherapy than double-positive tumors. Loss of PgR expression may be a result of pre-transcriptional alterations (copy number loss, mutation, epigenetic modifications), decreased transcription of the PGR gene (e.g. by microRNAs), and post-translational modifications (e.g. phosphorylation, sumoylation). Various processes involved in the down-regulation of PgR have distinct consequences on the biology of cancer cells. Occasionally, negative PgR status detected by immunohistochemical analysis is paradoxically associated with enhanced transcriptional activity of PgR that might be inhibited by antiprogestin treatment. Identification of the mechanism of PgR loss in each patient seems challenging, yet it may provide important information on the biology of the tumor and predict its responsiveness to the therapy.

scholarly journals Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis

2018 ◽  
Vol 110 (6) ◽  
pp. 568-580 ◽  
Author(s):  
Willemijne A M E Schrijver ◽  
Karijn P M Suijkerbuijk ◽  
Carla H van Gils ◽  
Elsken van der Wall ◽  
Cathy B Moelans ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Breast Cancer Metastases ◽  
Cancer Metastases ◽  
Receptor Conversion
Sign in / Sign up

Export Citation Format

Share Document